Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Q1 2025 Management View CEO Cameron Groome reported revenues of over $6 million for Q1, noting that this represents a 40% growth in recurring business compared to the same period last year, excluding ...

A team of biomolecular engineers, pathologists, and internal medicine specialists at the University of Texas Medical Branch, ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Recognition of specific antigen through the B-cell receptor (BCR) stimulates the activation of B cells, which ultimately results in the production of high-affinity antibodies and the provision of ...

This review seeks to familiarize the readers with RSV rapid antigen-detection tests, describe their performance characteristics and comment on their strengths and weaknesses. The authors will ...

Xilio Therapeutics (XLO) announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane ...

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen receptor inhibitors in prostate cancer.

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

High prostate-specific antigen levels before High-Intensity Focused Ultrasound were linked to higher recurrence and treatment failure in intermediate-risk prostate cancer.